Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia
- 2021
https://pubmed.ncbi.nlm.nih.gov/36640798/
An observational study, following a trial, to assess the immunogenicity and safety of standard dose versus fractional doses of COVID-19 vaccines (Pfizer-BioNTech or AstraZeneca) or standard dose Coronavac given as an additional dose after priming with Coronavac or AstraZeneca in healthy adults in Indonesia (BCOV-22)
- 2022
Immunogenicity and Safety Study of Half Dose of Moderna COVID-19 Vaccine Booster Heterologous in Adult Subjects in Indonesia. To compare the immunogenicity after booster dose between AstraZeneca and Sinovac priming group (MBCOV22)
- 2022
Long-term Outcome of Children with COVID-19 and treatment evaluation in Indonesia (LoCaTe)
- 2022
Delineating the risk factors and source of neonatal acquisition of multidrug resistant gram-negative bacteria in high burden countries in South-East Asia and the Pacific (NeoCol)
- 2024